TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04547296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Ringer's Solution
Description: After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Ringer's Solution
Description: After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
Study: NCT04898309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berinert®, 20 МЕ/ kg
Description: A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
Study: NCT05454189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reduced IPD Flush Schedule
Description: IPD flush every 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IPD Flush Schedule
Description: IPD flush every 4 weeks
Study: NCT04784169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: free middle turbinate flap
Description: Repairing low flow leak using free middle turbinate flap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vascularized nasoseptal flap
Description: Repairing low flow leak using fascia lata
Study: NCT05450263

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interoceptive exposure
Description: A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Interoceptive exposure
Description: A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.
Study: NCT06316180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drospirenone/estetrol 3mg/14.2mg
Description: Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
Study: NCT05285358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given via PIPAC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06471725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound
Description: The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound
Description: The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
Study: NCT05621460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50mL still water
Description: Drink 50mL still water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50mL still water
Description: Drink 50mL still water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50mL still water
Description: Drink 50mL still water immediately prior to head-up tilt test
Study: NCT04632381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zotatifin
Description: Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zotatifin
Description: Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zotatifin
Description: Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose injection, USP
Study: NCT05179005

Intervention type: DEVICE
Intervention: RibFix Advantage
Description: Intrathoracic rib fracture stabilization
Study: NCT06549907

Intervention type: OTHER
Intervention: Multi-omics testing
Description: Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.

Intervention type: OTHER
Intervention: MRI
Description: MRI will be conducted to investigate image characteristics during treatment
Study: NCT06421454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Pressure Ulcer will be treated with a melatonin cream daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Pressure ulcer will be treated with hydrogel daily as a comparator
Study: NCT06057103

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Description: Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Description: Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Description: Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A and Oseltamivir
Description: ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A and Oseltamivir
Description: ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A and Oseltamivir
Description: ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A and Oseltamivir
Description: ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A and Oseltamivir
Description: ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Description: Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Description: Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Description: Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A and Oseltamivir
Description: ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral
Study: NCT03188380

Intervention type: DIAGNOSTIC_TEST
Intervention: Plain abdominal radiography
Description: After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plain abdominal radiography
Description: After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound
Description: If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound
Description: If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
Study: NCT06571006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB
Study: NCT06569784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HSK31858
Description: A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
Study: NCT04478734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate doses of Thiamine y Biotin
Description: Thiamine 600 mg every day + Biotin 150mg every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High doses of Thiamine y Biotin
Description: Thiamine 1200 mg every day + Biotin 300mg every day
Study: NCT04718441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
Study: NCT05838716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Vitamin
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DXA scan

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dual X-ray Absorptiometry
Description: Undergo DXA scan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06067789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuraxial anesthesia
Description: Intervention arm participants will be allocated to neuraxial anesthesia.
Study: NCT05874596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model
Description: Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
Study: NCT05066139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPODIG-G program (coordination of supportive care)
Description: EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
Study: NCT05890573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bailing capsule
Description: 6 Bailing capsules,po,tid,12 weeks
Study: NCT04727164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003 and Triprilimab
Description: Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
Study: NCT05810649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freshly manufactured 35 kDa hyaluronan fragment
Description: One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
Study: NCT05902403

Intervention type: OTHER
Intervention: invasive mechanical ventilation
Description: Invasive mechanical ventilation for patients admitted to the ICU
Study: NCT06268457

Intervention type: PROCEDURE
Intervention: Chemoembolization with Doxorubicin
Description: * Identification of the main vessels afferent to the metastasis to be treated.~* Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~* Injection of embolizing material (hydrogel microspheres with doxorubicin)~* Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
Study: NCT04857333

Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan
Description: For patients with low-risk pulmonary nodules, follow-up CT scan is recommended

Intervention type: DRUG
Intervention: Antibiotics
Description: For pulmonary nodules with features of infectious disease, antibiotics is recommended

Intervention type: PROCEDURE
Intervention: Surgical Resection
Description: For persistent high-risk pulmonary nodules, surgical resection is recommended
Study: NCT05812625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myokinetic stretching technique
Description: Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Isometric Relaxation
Description: Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
Study: NCT05502055

Intervention type: OTHER
Intervention: Individual interviews
Description: One on One interviews by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: Individual interviews
Description: One on One interviews by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: Individual interviews
Description: One on One interviews by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: Individual interviews
Description: One on One interviews by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration

Intervention type: OTHER
Intervention: National Survey
Description: Survey conducted online and distributed nationally

Intervention type: OTHER
Intervention: National Survey
Description: Survey conducted online and distributed nationally

Intervention type: OTHER
Intervention: National Survey
Description: Survey conducted online and distributed nationally

Intervention type: OTHER
Intervention: National Survey
Description: Survey conducted online and distributed nationally
Study: NCT05964049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS treatment
Description: Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment
Description: The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
Study: NCT04808908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
Study: NCT05230654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(normal saline)
Description: Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
Study: NCT05248399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Group Problem Solving
Description: The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a \~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe \& Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care consists of the distribution of brochures containing COVID-19 prevention information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care consists of the distribution of brochures containing COVID-19 prevention information.